Genetically Modified Cells Attack Tumors
Posted on: Thursday, 21 December 2006, 12:12 CST
MEMPHIS, Tenn., Dec. 21 /PRNewswire/ -- Neuroblastoma tumors have been successfully treated in the lab with genetically modified cells that sought out and activated a chemotherapy drug placed directly at the cancer cells, according to investigators at St. Jude Children's Research Hospital and their colleagues at City of Hope National Medical Center (Duarte, CA) and the University of British Columbia (Vancouver, Canada). Neuroblastoma is a solid tumor that arises in a part of the nervous system outside the brain.
The researchers showed that the cells migrated to tumors regardless of how small the tumors were or where they were located in the body. The cells produced an enzyme that activated the chemotherapy drug CPT-11 (irinotecan) at the site of the tumors. A report on this work appears in the Dec. 20 issue of the journal PLoS ONE.
The study is the first to demonstrate that such cells, called neural stem- progenitor cells (NSPCs), can be used to target solid tumors that have spread. The fact that the drug is already used to treat cancers should make it easier to translate these laboratory findings to the clinic, the researchers noted.
Authors include Rebecca A. Bush, Doris A. Phelps, Joanna S. Remack, Karina Jin Yoon, Philip M. Potter and Mary K. Danks (St. Jude); Karen S. Aboody, Elizabeth Garcia, Marianne Z. Metz, Joseph Najbauer, Kristin A. Justus, Shanna Gillespie and Carlotta A. Glackin (City of Hope) and Seung U. Kim (University of British Columbia).
This work was supported in part by the National Institutes of Health/National Cancer Institute, Stop Cancer Foundation, Phi Beta Psi Sorority, Rosalinde and Arthur Gilbert Foundation, Neidorf Family Foundation, Marcus Foundation and ALSAC.
St. Jude Children's Research Hospital
St. Jude Children's Research Hospital is internationally recognized for its pioneering work in finding cures and saving children with cancer and other catastrophic diseases. Founded by late entertainer Danny Thomas and based in Memphis, Tenn., St. Jude freely shares its discoveries with scientific and medical communities around the world. No family ever pays for treatments not covered by insurance, and families without insurance are never asked to pay. St. Jude is financially supported by ALSAC, its fund-raising organization. For more information, please visit http://www.stjude.org/.
St. Jude Children's Research Hospital
CONTACT: Carrie Strehlau, +1-901-495-2295, orcarrie.strehlau@stjude.org, or Summer Freeman, +1-901-495-3061, orsummer.freeman@stjude.org, both of St. Jude Public Relations; or MarcKusinitz, Ph.D., Scientific Communications, St. Jude Children's ResearchHospital, +1-901-495-5020, or marc.kusinitz@stjude.org
Web site: http://www.stjude.org/
Source: PRNewswire
Related Articles
- CVS/pharmacy Kicks Off Annual Thanks and Giving(R) Campaign for the St. Jude Children's Research Hospital
- St. Jude Children's Research Hospital and UF Proton Therapy Institute to Begin Proton Therapy Clinical Trial
- Kmart Is Making Christmas Count With First Donation of the Season to St. Jude Children's Research Hospital(R)
- Video: St. Jude Children's Research Hospital Spotlights Successes and Challenges of Childhood Cancer
- St. Jude Children's Research Hospital(R), Chili's(R) Grill & Bar Kick-off Sixth Annual Create-A-Pepper to Fight Childhood Cancer Campaign
- Children's Brain Tumor Foundation's Tissue Bank Consortium May Solve Dire Problem in Pediatric Cancer Research
- An Overview of Testicular Germ Cell Tumors
- CVS/Pharmacy Joins St. Jude Children's Research Hospital to Help Save Children's Lives This Holiday Season
- Siemens Tim Technology Breaks All Records With 1,000th Installation at St. Jude Children's Research Hospital
- American Airlines Supports St. Jude Children's Research Hospital in Thanks And Giving Campaign
User Comments (0)

RSS Feeds